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Abstract. – A unifying thread over the wide
spectrum of diabetes might be the triggering of
innate immunological and inflammatory path-
ways leading to insulin resistance, β-cell dys-
function and β-cell destruction: the hybrid fea-
tures of type 1 and type 2 diabetes. In fact, hy-
perglycemia can arise from a deficit in insulin
action, insulin secretion, or both. 
Regularly exercising at moderate intensity
has been shown to efficiently and positively im-
pact upon physiological imbalances caused by
several morbid conditions. Even in different im-
munological dysfunctions, physical exercise has
been prescribed as a complementary therapeu-
tic strategy. In fact, as suggested by our obser-
vations, there is a putative inverse relationship
between autoimmunity markers (GAD, IA) and
exercise-derived energy expenditure in type 1
pre-diabetic subjects. Exercise also has been
shown to maintain muscle mitochondrial func-
tion and thus ability to maintain fuel metabolism
and islet cell function. An additional benefit is
the enhancement of antioxidant defense system
and thus reducing oxidative stress.
Therefore, the purpose of this review is to
address the importance of physical exercise in
a broad range of metabolic disorders that set
out a common milieu in which type 1 and type 2
diabetes could be identified as one extensive
syndrome.
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Introduction
The anti-inflammatory effects of exercise
against new-era metabolic diseases have been de-
bated for a long time, yet the causative mecha-
nisms for this are far to be clearly ascertained.
The continuing rise in prevalence and incidence
of low-grade chronic diseases such as diabetes,
obesity and the related cardiovascular diseases
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(CVD), for which aerobic moderate-intensity ex-
ercise has been shown to be protective, poses a
threat worldwide especially considering the
healthcare costs that these diseases entail. It has
been estimated that physical inactivity causes 6-
10% of all deaths from the major non-communi-
cable diseases (coronary heart disease, type 2 di-
abetes, and breast and colon cancer) and it is re-
sponsible for premature mortality by 9%, or
more than 5.3 of the 57 million deaths that oc-
curred worlwide in 2008; which is equal to stat-
ing that physical inactivity causes as many deaths
as tobacco does globally1,2. 
In the last decades much evidence has been ac-
cumulated documenting the many health benefits
of physical activity: regular exercise offers pro-
tection against all-cause mortality, primarily by
lowering the atherogenic profiles3, reduces rates
of CVD, hypertension, metabolic syndrome, type
2 diabetes, breast cancer and colon cancer. Fur-
thermore, physical training has been proved to be
effective in the treatment of several of these dis-
eases, including ischemic heart diseases4 and
heart failure5.
While it has been known for a long time that
physical exercise induces glucose-lowering ef-
fects by increasing insulin sensitivity and thus
represents a cornerstone in the therapy and pre-
vention of type 2 diabetes, it is still uncertain
whether exercise could be potentially beneficial
(and to which extent) in type 1 diabetes. In-
deed, regular exercise in people with type 1 di-
abetes does not necessarily lead to improved
glycemic control, and sustained execise re-
quires great care to adjust insulin administra-
tion and carbohydrate intake6,7. However, ongo-
ing observations indicate that subjects with
type 1 diabetes who follow a regular schedule
of aerobic training have prolonged “honey-
moon” – the early stage of the disease in which
insulin requirements are lower than in ad-
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Inflammetabolic Stress for 
Insulin-Producing β-cells
A considerable amount of evidence couples
type 1 and type 2 diabetes: even though they may
have diverse etiological and pathogenetic paths,
similar end-lines, such as pacreatic β-cell apopto-
sis and failure, may concern both diseases in hu-
mans15,16. Insulin dependence in fact may be
eventually occurring in both types, featured by a
peculiar time and rapidity of manifestation. Sev-
eral concepts and drivers have been proposed in
the last 2 decades in order to characterize and
classify the stereotypes of diabetes9,10. However,
an overlap of conditions and scenarios imposes a
proper understanding of the mechanisms so as to
guide both treatment and prevention of diabetes,
and to deal with its ultimate consequence of clin-
ical relevance: the insulin deficiency.
A vast array of situations in fact threathen the
functionality of the β-pancreatic mass, leading
the insulin-producing islets to their final demise,
i.e. the β–cell failure: increased stimulation of
the β-cells due to overfeeding; obesity; insulin
resistance; psychological stress; infections; low
physical activity; and all the modes promoting
islet inflammation and metabolic stress/unbal-
ance. It is possible that all these inflammetabolic
stressors stimulate or sometimes even initiate the
autoimmune β-islet disturbance17 (Figure 1).
Pancreatic islets of patients with type 2 dia-
betes exhibit signs of metabolic stress and in-
flammation, containing more macrophages and
secreting higher levels of interleukin (IL)-1β, IL-
6, IL-8, and MIP (macrophage inflammatory pro-
tein)-1α than normal islets15,18. Augmented pan-
creatic islet inflammation has been confirmed in
type 2 diabetic subjects by elevated expression of
other inflammatory cytokines derived from in-
nate immune cells, such as TNF-, IL-12, other
than IL-1β19. Hence, β-cell function might be im-
paired by innate immune mechanisms, leading to
β-cell failure, even in type 2 diabetes. However,
studies found an increased prevalence of islet-as-
sociated antigen-specific antibodies and T-cell re-
sponses in type 2 diabetic patients (targeting au-
toantigens like GAD65, IA2, proinsulin)20,21. Ad-
ditionally, a recent work reported an elevated
presence of B cells within islets of type 2 diabet-
ic individuals19. These latter findings support a
putative islet-specific adaptive immune process
in type 2 compared with healthy control subjects.
In summary, a broad scenario of β-cell stress
including lipotoxicity, glucotoxicity, endoplasmic
reticulum stress, chronic inflammation (derived
vanced type 1 diabetes. Once precised, exercise
may have a role beyond its insulin-mimetic ac-
tion, therefore reducing the autoimmune re-
sponse that in type 1 diabetes attacks and de-
stroys the β insulin-producing cells. Recent
studies have suggested that physical exercise
may interfere with immune system function
even at low intensity and duration: it has been
prescribed as a complementary therapeutic
strategy even in different immunological dys-
functions8. Moreover, modern environmental
factors including high-calorie and proinflam-
matory diets, sedentary lifestyles in sanitized
indoor environments, vitamin D insufficiency,
might be activating innate immune responses
promoting “hybrid” forms of diabetes9. The
available evidence indicates that, in fact, im-
paired insulin secretion (β-cell dysfunction) is
also a feature of type 2 diabetes, and insulin re-
sistance is also a risk factor for the develop-
ment of type 1 diabetes10. The incidences of
both types of diabetes have considerably in-
creased over the past half century in the devel-
oped world, regardless of any definitional fea-
tures, like age. “Double diabetes” has been re-
ferred to individuals who have both autoimmu-
nity against β-cells and insulin resistance 11,12.
Children, adolescents and adults with these hy-
brid forms of diabetes often report a family his-
tory of both type 1 and type 2 diabetes, central
obesity, and weaker immunogenetic markers
than those with classic type 1 diabetes (i.e.
lower-risk HLA genes, etc.)11. We detected au-
toimmunity markers in 10% of people with
type 2 diabetes in our database13.
In this perspective, physical exercise would
enable the achievement of better positions on the
glucose-tolerance curve by ameliorating insulin
sensitivity in every subject, either with type 2 or
type 1 diabetes (Figure 1). Traditionally, physical
exercise has been promoted in type 2 diabetes
where insulin action is deficient in the context of
insulin resistance and/or inappropriate insulin se-
cretion. However, even in type 1 diabetes, in the
dysregulation of immune system function, beta-
cell toxicity is mediated by a complex interplay
between oxidative stress and inflammation, for
which exercise could be protective14.
Given its powerful ability to modulate oxida-
tive stress and protect against chronic inflamma-
tory conditions, like those leading to autoimmu-
nity diseases, we want to review how favourably
exercise might affect these syndromic features in
the modern diabetogenic environment.
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stress. These exercise-related modifications, and
possibly adaptations, may be responsible for a
favourable inflammatory cytokine pattern and
may preserve the β-cell redox homeostasis – and
thus its insulin secreting capacity – against the
multiple-origin attacks directed towards β-cells
(Figure 1). 
Adipose Tissue and Inflammation 
Across all the aforementioned conditions, cer-
tainly diabetes and obesity represent the hall-
marks of the derangements in the complex inter-
play between metabolic and immune processes.
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from obesity, insulin resistance or both) is sup-
portive for a positive correlation between islet
autoimmunity and reduced β-cell function and -
mass seen in type 2 diabetic patients22,23. Howev-
er, the underlying mechanisms behind this are
presently unclear. 
The exercise-effects on the cytokine response
that may be anti-inflammatory and offer protec-
tion to β-cell against all these insults are envis-
aged. Depending on intensity, type and duration,
physical exercise is a potent inducer of physio-
logical changes at different levels, pertaining
stress hormones, energy crisis and oxidative
Figure 1. Environmental syndromic thread affecting glucose homeostasis. The relationship between insulin sensitivity and
beta-cell function is hyperbolic. When the homeostatic ability of the glucose-insulin system is healthy, changes in insulin sensi-
tivity (ISI) tend to be compensated by changes in beta-cell secretion (φ) of opposite sign. This means that, by riding the “hyper-
bola”, glucose homeostasis can be preserved with a reduction in insulin sensitivity that corresponds to an augmented insulin se-
cretion. If this does not occur, a growing insulin resistance (left-handed red arrow) might be leading to type 2 diabetes. Con-
versely, a not-compensated insulin secretion, perhaps owing to autoimmunity attacks (downward red arrow), might progressive-
ly destroy β-cell mass, resulting in type 1 diabetes. However, environmental multiple-differentiated attacks (syndromic diabeto-
genic factors, in the spined diagram) can unhealthly drag glucose homeostasis to the β-cell dysfunction area, upon the triggering
of both axes (φ, ISI). The green therapy vector, as a resultant from a potentially combined strategy of exercise and drugs, coun-
teracts all these diabetogenic factors towards an ameliorated glucose tolerance area. Actually, according to our observations,
physically exercise alone may be helping individuals in two way by both enhancing insulin sensitivity (increasing insulin action)
and β-cell function (through the reduction of the deleterious effects of autoimmunity). The two effects are likely to combine to-
gether and produce a substancial gain in glucose tolerance. Potentially, they may even delay the onset of frank diabetes.
circulating monocytes to adipose tissue and pro-
motes their differentiation into adipose tissue
macrophages30,38. 
Akin to macrophages, T and B cells – autore-
active species of adaptive immune response –
were found to infiltrate visceral adipose tissue in
obese humans39 and mice40,41. Moreover, in DIO
(diet-induced obesity)-mice, T- or B-cell deple-
tion or genetic deficiency resulted to ameliorate
insulin resistance, confirming a tight thread sur-
rounding adaptive immunity, obesity-related in-
flammation and insulin resistance40-43.
The addictive involvement of all these cell
types (both innate and adaptive immune cells) in
metabolic homeostasis opens an appealing re-
search area yet to be fully explored – the im-
munometabolism44 – and raises the possibility
that obesity-related insulin resistance and -in-
flammation may have a defined autoimmune
component45.
It has been shown that exercise is capable of
modifying structure, inflammatory- and immune
responses in visceral and subcutaneous adipose
tissue46; therefore it emerges as substantial inter-
vention to blunt, harness, counteract (and possi-
bly revert) all this cluster of immunometabolic
disturbances and, to some extent, even when au-
toimmune-based.
The challenge would be to understand how
large is this therapeutical window for the benefi-
cial effects of exercise.
Skeletal Muscle and Inflammation
Similarly to adipose tissue, a parallel analysis
can be made for the skeletal muscle, recently ad-
vocated as a proper endocrine organ, giving its
secretory capacity to release several proteins, cy-
tokines and even hormone-like mediators47.
These factors exert specific endocrine effects
within the muscle cells themselves or on distant
organs too. Put in this way, skeletal muscle may
produce hundred of “myokines” via paracrine,
autocrine, endocrine mechanisms to modulate
signalling pathways either locally or by releasing
these proteins into the circulation directly48.
Considering that the majority of the
adipokines are proinflammatory, myokines se-
creted by muscle fibres could balance the harm-
ful adipokine-mediated effects typical of (or
leading to) chronic diseases. In fact, upon con-
traction, skeletal muscle may produce several
proteins – altering the so-called “myokine re-
sponse” – and therefore physical activity could
Inflammation, in a chronic low-grade systemic
mode, appears as a common denominator of sev-
eral pathologies24. Quite recently, fascinating
studies proved that obesity and diabetes are asso-
ciated with markers of activated innate immune
system and inflammation: chronic, low-grade in-
flammation has been detected in multiple tissues
of obese individuals25, especially when obesity is
exacerbated by the additional diagnosis of dia-
betes26,27.
Although the ethiology is matter of debate, it
probably implies the activation of cellular stress
responses via super-abundant lipid accumulation
within key-cells such as adipocytes or hepato-
cytes28-30. Excessive hepatic lipid accumulation
is known to be linked to hepatic insulin resis-
tance, hepatosteatosis and liver inflammation
(both in obesity-induced and not-) via multiple
deleterious mechanisms31,32. Adipocytes are rec-
ognized as crucial sites in the generation of in-
flammatory responses and mediators: here, a
group of peptide hormones and cytokines,
named “adipokines”33, are produced and secret-
ed to regulate fuel use and lipid storage in other
peripheral tissues. Among proinflammatory
adipokines, TNF-α is a potent activator of vari-
ous signal trasduction cascades, including those
as critical inhibitors of insulin action: the dis-
covery of elevated levels of TNF-α in obese
mice provided the first evidence that subclinical
inflammatory processes accompany insulin re-
sistance and metabolic dysfunction, anticipating
type 2 diabetes34. Expanded adipose tissue is as-
sociated with heightened production of other
proinflammatory adipokines such as IL-6,
retinol-binding protein-4 (RBP4), IL-1833. Con-
versely, amounts of adipokines with anti-inflam-
matory functions, like adiponectin, are found re-
duced in accumulated adipose tissue compared
with the proinflammatory ones33. Leptin is an-
other regulatory hormone released by adipocytes
into the circulation, acting as “anti-diabeto-
genic”, by influencing the hypothalamus to con-
trol appetite35,36. Intriguingly, this extended im-
munometabolic framework can be triggered and
modulated by physical exercise.
In adipocytes, chemokines and cytokines may
work in network upon diverse metabolic stimula-
tion and may even interact with other effectors of
the immune system, including immune cells, like
T-cells, macrophages and dendritic cells37. It has
been documented that, in adipocytes, metabolic
stress elicits the release of MCP-1, a chemoat-
tractant cytokine which regulates migration of
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represent a potential defense against proinflam-
matory modes. In addition, miokynes may target
other organs, thus, a new explorable crosstalk
arises not only between skeletal muscle and adi-
pose tissue but also with liver, pancreas, bones
and brain (Figure 2). Taken together, these obser-
vations raise the question of what are these
myokines, and specifically, which of them are
exercise-induced/modulated to counteract in-
flammation. A novel paradigm on how skeletal
muscle communicates with other organs has to
be addressed.
A great deal of interest has been given to myo-
statin, one of the first muscle factor described as
“myokine”. Secreted into the circulation, myo-
statin is a robust growth-inhibitor and, as such,
its deletion promotes skeletal muscle hypertro-
phy49 along with its elected inhibitor, follistatin.
3713
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This latter might be referred as “hepatokine”,
since it is released from the liver to regulate mus-
cle expression of myostatin in relation to exer-
cise. Follistatin proves the existence of a possible
crosstalk between muscle and liver, during and
following exercise50. Myostatin is also involved
in the maintainance of metabolic homeostasis
and modulation of adipose tissue function and
mass51-54. Increased muscle and circulating levels
of myostatin were found in obese individuals55.
Myostatin inhibition decreases adiposity and
ameliorates muscle weakness56. Endurance and
resistance exercise lower myostatin expression in
humans and rodents57. 
IL-6 has been recognized as a myokine proto-
type, given its master role in immuno- and in-
flammatory-modulating metabolism in response
to muscle contractions48. Depending on intensity,
Figure 2. Organ exercise-mediated crosstalk contributing to the anti-inflammatory pattern.Multiple organs are affected by
exercise, initiating diverse anti-inflammatory responses. In the brain, the hypothalamic-pituitary-adrenal axis is activated and it in-
duces adrenal cortex and medulla to produce cortisol and adrenaline, respectively. These two hormones, in turn, suppress the re-
lease of the proinflammatory tumor necrosis factor (TNF)-citokines by monocytes. Protein and mRNA expression of follistatin,
another member of TNF-superfamily, are markedly increased in the liver following exercise to inhibit myostation action. In other
organs and tissues (liver, spleen, muscle) exercise can also lower the expression and the activation of Toll-like receptor 4 (TLR4),
thereby reducing adipose tissue infiltration and other proinflammatory cytokines. In adipose tissue, a switch from M1 to M2
macrophage phenotype may inhibit the release of the proinflammatory cytokines – interleukin-6 (IL-6) and TNF – and increase
the production of anti-inflammatory cytokines, such as IL-10 and adiponectin. IL-10 may be also upregulated by the increased cir-
culating numbers of regulatory T cells (Treg). Contracting muscles are responsable for a complex cascade which ultimately results
to be anti-inflammatory: increases in IL-6 determine a downregulation of TNF as well as an upregulation of IL-10 and IL-ra.
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duration of exercise, rescruited mass, one’s en-
durance capacity, circulating levels of IL-6 in-
crease in an exponential fashion 58. Muscle cells
are the primary source of IL-6 during exercise,
although IL-6 may have systemic effects on the
liver and adipose tissue and it increases insulin
sescretion via up-regulation of GLP-159,60.
Through AMPK activation, IL-6 enhances in-
sulin-stimulated glucose uptake both in skeletal
muscle and adipose tissue, and it increases lipid
oxidation locally (intra-muscle) and whole-
body61,62. BDNF (brain-derived neurotrophic fac-
tor) is also involved in muscle AMPK-mediated
fat oxidation63 and its circulating levels increase
with aerobic exercise, especially with high-inten-
sity exercise64. In the brain, BDNF increases neu-
ronal connections and is crucial for some aspects
of memory65. Plasma transient appearance of IL-
6 following exercise is of paramount relevance
because it induces the production of the anti-in-
flammatory cytokines IL-1ra, and IL-1066. Im-
portantly, skeletal muscle production of IL-6 dur-
ing exercise inhibits, the release of proinflamma-
tory cytokine TNF-α, independently67. As energy
sensor, IL-6mRNA expression and protein con-
tent are inversely correlated with carbohydrate
availability; specifically they are increased as the
intramuscular glycogen levels are low68. Other
potential roles of IL-6 are stimulation of muscle
growth69,70 and angiogenesis71. A myriad of stud-
ies on the involvement of IL-6 in the pathogene-
ses of obesity, insulin resistance, type 1 and type
2 diabetes, confirm the great expectations from
IL-6 as a candidate physiological mediator of β-
cell protector14,60,72-74, possibly via exercise47.
IGF-1 and FGF-2 are involved in bone forma-
tion75. Irisin is a myokine discovered to have a
role in “browning” of white adipose tissue, i.e. in
driving brown-fat-like development of white adi-
pose tissue, with high favourable metabolic sig-
nificance76. 
Despite its anabolic and anti-catabolic effects,
mainly by diminishing lipid deposition, IL-15
cannot be reported as a true myokine, since stud-
ies describing its secretion from muscle cells are
lacking48. However, muscle-derived IL-15 has
been advocated as one of the mediators of the an-
ti-obesity effects of exercise77.
If skeletal muscle cells were found to possess
a “humoral” factor more than 50 years ago78, a
new vista of a branched-out muscle crosstalk
with other organs requires increasingly sophisti-
cated approaches to understand the critical nodes
of immuno- and energy metabolism. Future exer-
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cise-studies could yield transformative research
outcomes in these areas, and hopefully unveil
how these pathways are disrupted in a number of
inactivity-related diseases.
The Anti-Inflammatory Effects of Exercise
Physical exercise is generally prescribed, to-
gether with diet and drugs, in type 2 diabetes
therapy because of its well-established glucose-
lowering effects and insulin-mimetic actions.
However, exercise may be pleiotropic and coun-
terbalance proinflammatory cytokines activity,
impacting significantly on both immunoregula-
tion and non-immune events in many cell types
and tissues outside the immune system.
Exercise and autoimmunity. We collected im-
munological and metabolic data in patients
with type 1 diabetes (male n=6; female n=6;
BMI 24.6±1 kg/m2; 46±4.9 years, mean and
SE) and analyzed them with energy expendi-
ture data, assessed by a seven-day physical ac-
tivity self-completed diary, to understand
whether exercise could favourably affect au-
toimmunity: a regression results analysis
showed an inverse relationship between au-
toimmunity markers (GAD, IA) and weekly
energy expenditure (EE) derived from physical
exercise13. In addition, type 1 diabetic subjects
with higher physical activity index than their
peer-controls were found to have a prolonged
“honeymoon-period”, and reduced exogenous
insulin requirements, respectively. This period
of time in the course of diabetes onset has
been seen to last as long as 10-15 years in
some athletes. These observations suggest that
exercise may positively modulate immune sys-
tem function. In a retrospective analysis79, 10-
year followed-up subjects with type 1 diabetes
showed ameliorated scores of disease manage-
ment and quality of life.
Furthermore, our studies showed that physical
activity may be helping and preventive for β-
cells transplanted recipients by counteracting
diabetic symptoms and mitigating the side ef-
fects of immunosuppressive drugs and graft
dysfunction80. In fact, in these patients, pro-
gressive insulin resistance might be a probable
outcome of immunosuppression and chronic
inflammation.
According to other studies14, the anti-inflamma-
tory effect of exercise mediated by upregula-
tion of Th2 cytokines may even lead to a pro-
tective response against the autoimmune
process directed to β-cells.
M2-M1 shift in adipose tissue. In inflammed
adipose tissue, like in obesity, there is a shift
in the immune cell profile81. Resident M2 anti-
inflammatory macrophages decrease while M1
proinflammatory macrophages increase. A
preferential recruitment of M1-type
macrophages has been associated with the ini-
tial state of inflammation in adipose tissue82.
This state precedes both local and systemic in-
sulin resistance. Inflammation can be hence at-
tenuated by chronic exercise in high-fat fed
mice, both with reduced macrophage infitra-
tion and a switch from an M1 to an M2
macrophage phenotype.
IL-6. Along with the reduction of visceral fat
mass, and subsequently via a decrease in
proinflammatory adipokine secretion, another
exercise anti-inflammatory mechanism can be
ascribed to the release of IL-6 from contract-
ing muscles. Literature is overwhelmed by
studies on IL-6, nevertheless its role remains
contorversial83. IL-6 itself is a proinflammato-
ry acute-phase cytokine and its plasma con-
centrations were seen elevated in subjects with
impaired glucose tolerance84-86. High plasma
levels of IL-6 are also associated with physical
inactivity87 and metabolic syndrome88. Howev-
er, IL-6 mediates a number of anti-inflamma-
tory responses: the transient rise in circulating
levels of IL-6 during exercise (up to 100-fold
in response to it)89-91 stimulates the appeare-
ance in the blood stream of the anti-inflamma-
tory cytokines IL-10 and IL-1ra and the re-
lease of cortisol from adrenal gland66. This
hormone, in turn, as well as adrenaline, in-
hibits the release of proinflammatory cytokine
TNF-α by monocytes92 (Figure 2). IL-6 itself
downregulates the production of TNF-α as in-
dicated by in vitro and animal studies93-95.
IL-1ra. IL-1ra belongs to the IL-1 family and it
is primarily produced by monocytes and
macrophages. It inhibits the proinflammatory
actions of IL-1β96. While IL-6 levels tend to
peak at the cessation of exercise, circulating
levels of IL-1ra are modestly heightened at the
end of exercise and then increase remarkably
in the hours following exercise66. This con-
firms the fact that IL-6 is a major inducer of
IL-1ra. IL-1β is a master cytokine, controlling
local and systemic inflammation: its plasma
levels are increased in a vast number of meta-
bolic diseases97. 
IL-10. IL-10 plays an important role in orches-
trating an anti-inflammatory reaction, espe-
cially by activating macrophage and mono-
cytes. It inhibits the production of several
proinflammmatory chemokines like IL-1β, IL-
1α, TNF- α, IL-8, therefore, compromisig the
inflammatory capacity of effector T cells98,99.
Ultimately, IL-10 downregulates the adaptive
immune responses and minimizes inflamma-
tion of damaged tissues98. Circulating levels of
IL-10 were found low in obese subjects100.
CRP. Some longitudinal studies have showed that
regular exercise training induces a reduction in
C-reactive protein (CRP)101,102, a sound marker
of systemic low-grade inflammation (Table I).
CRP has a role both in induction of anti-inflm-
matory cytokines in circulation monocytes, and
in suppressing the synthesis of proinflammato-
ry cytokines in tissue macrophages. Plasma
CRP leveles were seen mildly increased the
day after prolonged exercise103.
TLRs. Limited evidence (confined to in vitro and
murine models) points to a downregulation of
Toll-like-receptors (TLR) with acute exer-
cise104. TLRs are transmembrane proteins that
detect microbial pathogens and they are in-
volved in the recognition of endotoxins, like
heat shock protein (hsp)105. Activation of TLRs
results in a proinflammatory signalling cas-
cades that have been associated with sedentary
lifestyle ad systemic inflammation106. Howev-
er, the physiological explanation behind the
exercise-induced decrease in TLR expression
remains to be clearly established.
Heat shock proteins. Exercise may also exert an
anti-inflammatory effect by inducing the
espression of 70-kDa family of heat shock
protein (hsp70)107. In turn, the hsp70 initiation
has been reported to suppress the proinflam-
matory activation of the nuclear transcription
factor of κB family (NF-κB)108. NF-κB was
shown as the first redox-sensitive eukaryotic
transcription factor able to respond directly to
oxidative stress in many cell types109,110. Basi-
cally NF-κB amplifies immune- and inflam-
matory responses in all cells. Hsp pathways
have been also correlated with the modulation
of peripheral autoimmunity111.
Regulatory T cells. Exercise training was found
to mobilize regulatory T cells (Treg), which
suppress immune responses112. In fact, Treg
cells are a considerable source of the anti-in-
flammatory cytokine IL-10113. Moreover, de-
pletion of CD4+CD25+ Treg can lead to autom-
munity and enhances immune response to for-
eign antigens114,115.
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Limitations. In vitro measures have been exten-
sively used to model the complex situation in
humans, and only peripheral blood measure-
ments have been performed in the majority of
human studies investigating immunological re-
sponses to exercise113. Although determinant to
mimic in vivo settings, animal studies are in-
conclusive to describe univocal inflammatory
patterns. Non-obese diabetic (NOD) mice, as
the elected experimental model analogous to
human type 1 diabetes, can exemplify that
dilemma116. High-intensity exercise training in
a mouse running model resulted to increase
expression of circulating Treg cells more than a
moderate-intensity regime, implying an aug-
mented anti-inflammatory effect with an high-
er-intensity training112. This notion is support-
ed by other studies and wonders on the suited
volume of exercise to maximize beneficial
health effects117,118.
Consistent data from observational studies show-
ing a link between self-reported levels of phys-
ical activity and inflammatory- or autoimmune
biomarkers, as well as some promising data
from randomized controlled trials119, indicate
that increasing aerobic activity could be effec-
tive for reducing chronic inflammation and in-
sulin requirements in different dysmetabolic
patients (Table I). However, the magnitude of
the effects of physical activity on inflammato-
ry mediators, and the amount of exercise nec-
essary to produce clinically meaningful reduc-
tions in inflammations, has to be properly ad-
dressed. In this perspective, further human tri-
als are warranted in order to tailor the optimal
training regimes. 
Integrative View and Concluding 
Remarks 
Cytokines are involved in mediating the benefi-
cial health effects of exercise in a crosstalk with
organs and tissues (Figure 2), and they therefore
play pivotal role in the protection against several
diseases associated with systemic low-grade in-
flammation (Figure 1). This latter results in turn
correlated to a broad immuno-metabolic scenario.
It is nowadays clear that marked immune aberran-
cies are linked to several metabolic diseases. Thus
exercise emerges as a cornerstone in the preven-
tion, cure and treatment of all-species metabolic
disturbances. In the view of novel pharamacologi-
cal therapies targeted at different key organ/tis-
sues, it is anyway harsh to conceive one universal
drug capable of combatting all the diverse root
causes. Intense efforts have been even made to
discover active compunds that mimic or potentiate
the effects of exercise training – the most notably
“exercise mimetics”. Nonetheless, it will be very
improbable that one pill can reproduce the multi-
ple health-promoting benefits rising from contract-
ing muscles. In fact, researchers have even advo-
cated the “polypill”120 concept for the role of exer-
cise, alluding to such wide-ranging positive pertur-
bations on cells, tissues and organs.
The ultimate consideration of exercise as a
panacea would be utterly esthetic if we just en-
courage people to do more, to be more phsycally
active in a pandemic context of environmental
syndromic factors.
––––––––
Funding
Studies in NOD mice and in individuals with type 1 diabetes
were supported in part by a grant from European Commis-
sion (FP7-PEOPLE-2009-IRSES, Project “IMMEEDIA”
no. 247472).
––––––––––––––––-–––
Conflict of Interest
No potential conflicts of interest relevant to this article were
reported.
References
1) DAS P, HORTON R. Rethinking our approach to
physical activity. Lancet 2012; 380:189-190.
2) LEE IM, SHIROMA EJ, LOBELO F, PUSKA P, BLAIR SN,
KATZMARZYK PT, Lancet Physical Activity Series
Working Group. Effect of physical inactivity on
major non-communicable diseases worldwide: An
analysis of burden of disease and life expectancy.
Lancet 2012; 380: 219-229.
3) BLAIR SN, CHENG Y, HOLDER JS. Is physical activity or
physical fitness more important in defining health
benefits? Med Sci Sports Exerc 2001; 33: S379-
399; S419-420.
4) JOLLIFFE JA, REES K, TAYLOR RS, THOMPSON D,
OLDRIDGE N, EBRAHIM S. Exercise-Based rehabilita-
tion for coronary heart disease. Cochrane Data-
base Syst Rev 2000; 4: CD001800.
5) PIEPOLI MF, CONRAADS V, CORRÀ U, DICKSTEIN K, FRAN-
CIS DP, JAARSMA T, MCMURRAY J, PIESKE B, PIOTROWICZ
E, SCHMID JP, ANKER SD, SOLAL AC, FILIPPATOS GS,
HOES AW, GIELEN S, GIANNUZZI P, PONIKOWSKI PP. Ex-
ercise training in heart failure: From theory to
practice. A consensus document of the heart fail-
ure association and the european association for
cardiovascular prevention and rehabilitation. Eur J
Heart Fail 2011; 13: 347-357.
3717
Exercise and the Diabetic Syndrome
3718
6) LUMB AN, GALLEN IW. Diabetes management for in-
tense exercise. Curr Opin Endocrinol Diabetes
Obes 2009; 16: 150-155.
7) GALASSETTI P, RIDDELL MC. Exercise and type 1 dia-
betes (T1DM). Compr Physiol 2013; 3: 1309-1336.
8) COSTA ROSA LF. Exercise as a time-conditioning ef-
fector in chronic disease: A complementary treat-
ment strategy. Evid Based Complement Alternat
Med 2004; 1: 63-70.
9) WENTWORTH JM, FOURLANOS S, HARRISON LC. Reap-
praising the stereotypes of diabetes in the mod-
ern diabetogenic environment. Nat Rev En-
docrinol 2009; 5: 483-489.
10) FLOREZ JC. Clinical review: The genetics of type 2
diabetes: A realistic appraisal in 2008. J Clin En-
docrinol Metab 2008; 93: 4633-4642.
11) FOURLANOS S, DOTTA F, GREENBAUM CJ, PALMER JP,
ROLANDSSON O, COLMAN PG, HARRISON LC. Latent
autoimmune diabetes in adults (LADA) should be
less latent. Diabetologia 2005; 48: 2206-2212.
12) FOURLANOS S, VARNEY MD, TAIT BD, MORAHAN G,
HONEYMAN MC, COLMAN PG, HARRISON LC. The ris-
ing incidence of type 1 diabetes is accounted for
by cases with lower-risk human leukocyte antigen
genotypes. Diabetes Care 2008; 31: 1546-1549.
13) LUZI L, CODELLA R, LAURIOLA V, MESSINGER S, ALEJAN-
DRO R, RICORDI C. Immunomodulatory effects of ex-
ercise in type 1 diabetes mellitus. Diabetes 2011;
60: A209-A210.
14) KRAUSE MDA S, DE BITTENCOURT PI. Type 1 diabetes:
Can exercise impair the autoimmune event? The
l-arginine/glutamine coupling hypothesis. Cell
Biochem Funct 2008; 26: 406-433.
15) DONATH MY, STØRLING J, MAEDLER K, MANDRUP-
POULSEN T. Inflammatory mediators and islet beta-
cell failure: A link between type 1 and type 2 dia-
betes. J Mol Med (Berl) 2003; 8: 455-470.
16) MUOIO DM, NEWGARD CB. Mechanisms of disease:
Molecular and metabolic mechanisms of insulin
resistance and beta-cell failure in type 2 diabetes.
Nat Rev Mol Cell Biol 2008; 9: 193-205.
17) LUDVIGSSON J. Why diabetes incidence increases--
a unifying theory. Ann N Y Acad Sci 2006; 1079:
374-382.
18) EHSES JA, PERREN A, EPPLER E, RIBAUX P, POSPISILIK JA,
MAOR-CAHN R, GUERIPEL X, ELLINGSGAARD H, SCHNEI-
DER MK, BIOLLAZ G, FONTANA A, REINECKE M, HOMO-
DELARCHE F, DONATH MY. Increased number of islet-
associated macrophages in type 2 diabetes. Dia-
betes 2007; 56: 2356-2370.
19) BUTCHER MJ, HALLINGER D, GARCIA E, MACHIDA Y,
CHAKRABARTI S, NADLER J, GALKINA EV, IMAI Y. Associ-
ation of proinflammatory cytokines and islet resi-
dent leucocytes with islet dysfunction in type 2 di-
abetes. Diabetologia 2014; 57: 491-501.
20) BROOKS-WORRELL B, NARLA R, PALMER JP. Islet autoim-
munity in phenotypic type 2 diabetes patients. Di-
abetes Obes Metab 2013; 15: 137-140.
21) SARIKONDA G, PETTUS J, PHATAK S, SACHITHANANTHAM S,
MILLER JF, WESLEY JD, CADAG E, CHAE J, GANESAN L,
MALLIOS R, EDELMAN S, PETERS B, VON HERRATH M.
CD8 t-cell reactivity to islet antigens is unique to
type 1 while CD4 t-cell reactivity exists in both
type 1 and type 2 diabetes. J Autoimmun 2014;
50: 77-82.
22) SUBAUSTE A, GIANANI R, CHANG AM, PLUNKETT C,
PIETROPAOLO SL, ZHANG YJ, BARINAS-MITCHELL E,
KULLER LH, GALECKI A, HALTER JB, PIETROPAOLO M.
Islet autoimmunity identifies a unique pattern of
impaired pancreatic beta-cell function, markedly
reduced pancreatic beta cell mass and insulin re-
sistance in clinically diagnosed type 2 diabetes.
Plos One 2014; 9: e106537.
23) PIETROPAOLO M, BARINAS-MITCHELL E, PIETROPAOLO SL,
KULLER LH, TRUCCO M. Evidence of islet cell autoim-
munity in elderly patients with type 2 diabetes. Di-
abetes 2000; 49: 32-38.
24) HOTAMISLIGIL GS. Inflammation and metabolic disor-
ders. Nature 2006; 444: 860-867.
25) SHOELSON SE, LEE J, GOLDFINE AB. Inflammation and in-
sulin resistance. J Clin Invest 2006; 116: 1793-1801.
26) WELLEN KE, HOTAMISLIGIL GS. Inflammation, stress,
and diabetes. J Clin Invest 2005; 115: 1111-1119.
27) DANDONA P, ALJADA A, BANDYOPADHYAY A. Inflamma-
tion: The link between insulin resistance, obesity
and diabetes. Trends Immunol 2004; 25: 4-7.
28) BRUUN JM, LIHN AS, PEDERSEN SB, RICHELSEN B.
Monocyte chemoattractant protein-1 release is
higher in visceral than subcutaneous human adi-
pose tissue (AT): Implication of macrophages res-
ident in the AT. J Clin Endocrinol Metab 2005; 90:
2282-2289.
29) CINTI S, MITCHELL G, BARBATELLI G, MURANO I, CERESI E,
FALOIA E, WANG S, FORTIER M, GREENBERG AS, OBIN
MS. Adipocyte death defines macrophage localiza-
tion and function in adipose tissue of obese mice
and humans. J Lipid Res 2005; 46: 2347-2355.
30) XU H, BARNES GT, YANG Q, TAN G, YANG D, CHOU CJ,
SOLE J, NICHOLS A, ROSS JS, TARTAGLIA LA, CHEN H.
Chronic inflammation in fat plays a crucial role in
the development of obesity-related insulin resis-
tance. J Clin Invest 2003; 112:01821-1830.
31) SAMUEL VT, SHULMAN GI. Mechanisms for insulin re-
sistance: Common threads and missing links. Cell
2012; 148: 852-871.
32) CAI D, YUAN M, FRANTZ DF, MELENDEZ PA, HANSEN L,
LEE J, SHOELSON SE. Local and systemic insulin re-
sistance resulting from hepatic activation of IKK-
beta and NF-kappaB. Nat Med 2005; 11: 183-190.
33) OUCHI N, PARKER JL, LUGUS JJ, WALSH K. Adipokines
in inflammation and metabolic disease. Nat Rev
Immunol 2011; 11: 85-97.
34) HOTAMISLIGIL GS, SHARGILL NS, SPIEGELMAN BM. Adi-
pose expression of tumor necrosis factor-alpha:
Direct role in obesity-linked insulin resistance.
Science 1993; 259: 87-91.
35) ZHANG Y, PROENCA R, MAFFEI M, BARONE M, LEOPOLD
L, FRIEDMAN JM. Positional cloning of the mouse
obese gene and its human homologue. Nature
1994; 372: 425-32.
R. Codella, L. Luzi, L. Inverardi, C. Ricordi
36) FRIEDMAN JM. The function of leptin in nutrition,
weight, and physiology. Nutr Rev 2002; 60: S1-14;
S68-84, 85-87.
37) FANTUZZI G. Adipose tissue, adipokines, and in-
flammation. J Allergy Clin Immunol 2005; 115:
911-919; quiz 920.
38) CHEN A, MUMICK S, ZHANG C, LAMB J, DAI H, WEIN-
GARTH D, MUDGETT J, CHEN H, MACNEIL DJ, REITMAN
ML, QIAN S. Diet induction of monocyte chemoat-
tractant protein-1 and its impact on obesity. Obes
Res 2005; 13: 1311-1320.
39) VIARDOT A, HEILBRONN LK, SAMOCHA-BONET D, MACKAY
F, CAMPBELL LV, SAMARAS K. Obesity is associated
with activated and insulin resistant immune cells.
Diabetes Metab Res Rev 2012; 28: 447-454.
40) WINER S, CHAN Y, PALTSER G, TRUONG D, TSUI H,
BAHRAMI J, DORFMAN R, WANG Y, ZIELENSKI J, MAS-
TRONARDI F, MAEZAWA Y, DRUCKER DJ, ENGLEMAN E,
WINER D, DOSCH HM. Normalization of obesity-as-
sociated insulin resistance through immunothera-
py. Nat Med 2009; 15: 921-929.
41) NISHIMURA S, MANABE I, NAGASAKI M, ETO K, YAMASHITA
H, OHSUGI M, OTSU M, HARA K, UEKI K, SUGIURA S,
YOSHIMURA K, KADOWAKI T, NAGAI R. CD8+ effector T
cells contribute to macrophage recruitment and
adipose tissue inflammation in obesity. Nat Med
2009; 15: 914-920.
42) DEFURIA J, BELKINA AC, JAGANNATHAN-BOGDAN M, SNY-
DER-CAPPIONE J, CARR JD, NERSESOVA YR, MARKHAM D,
STRISSEL KJ, WATKINS AA, ZHU M, ALLEN J, BOUCHARD
J, TORALDO G, JASUJA R, OBIN MS, MCDONNELL ME,
APOVIAN C, DENIS GV, NIKOLAJCZYK BS. B cells pro-
mote inflammation in obesity and type 2 diabetes
through regulation of t-cell function and an inflam-
matory cytokine profile. Proc Natl Acad Sci U S A
2013; 110: 5133-5138.
43) WINER DA, WINER S, SHEN L, WADIA PP, YANTHA J,
PALTSER G, TSUI H, WU P, DAVIDSON MG, ALONSO MN,
LEONG HX, GLASSFORD A, CAIMOL M, KENKEL JA, TEDDER
TF, MCLAUGHLIN T, MIKLOS DB, DOSCH HM, ENGLEMAN
EG. B cells promote insulin resistance through
modulation of T cells and production of pathogenic
igg antibodies. Nat Med 2011; 17: 610-617.
44) MATHIS D, SHOELSON SE. Immunometabolism: An
emerging frontier. Nat Rev Immunol 2011; 11: 81.
45) TSAI S, CLEMENTE-CASARES X, REVELO XS, WINER S,
WINER DA. Are obesity-related insulin resistance
and type 2 diabetes autoimmune diseases? Dia-
betes 2015; 64: 1886-1897.
46) STANFORD KI, MIDDELBEEK RJ, TOWNSEND KL, LEE MY,
TAKAHASHI H, SO K, HITCHCOX KM, MARKAN KR, HELL-
BACH K, HIRSHMAN MF, TSENG YH, GOODYEAR LJ. A
novel role for subcutaneous adipose tissue in ex-
ercise-induced improvements in glucose home-
ostasis. Diabetes 2015; 64: 2002-2014.
47) PEDERSEN BK, FEBBRAIO MA. Muscles, exercise and
obesity: Skeletal muscle as a secretory organ.
Nat Rev Endocrinol 2012; 8: 457-465.
48) PEDERSEN BK, FEBBRAIO MA. Muscle as an en-
docrine organ: Focus on muscle-derived inter-
leukin-6. Physiol Rev 2008; 88: 1379-1406.
49) MCPHERRON AC, LAWLER AM, LEE SJ. Regulation of
skeletal muscle mass in mice by a new tgf-beta
superfamily member. Nature 1997; 387: 83-90.
50) HANSEN J, BRANDT C, NIELSEN AR, HOJMAN P,
WHITHAM M, FEBBRAIO MA, PEDERSEN BK, PLOMGAARD
P. Exercise induces a marked increase in plasma
follistatin: Evidence that follistatin is a contraction-
induced hepatokine. Endocrinology 2011; 152:
164-171.
51) ZHAO B, WALL RJ, YANG J. Transgenic expression of
myostatin propeptide prevents diet-induced obesi-
ty and insulin resistance. Biochem Biophys Res
Commun 2005; 337: 248-255.
52) GUO T, JOU W, CHANTURIYA T, PORTAS J, GAVRILOVA O,
MCPHERRON AC. Myostatin inhibition in muscle, but
not adipose tissue, decreases fat mass and im-
proves insulin sensitivity. Plos One 2009; 4:
e4937.
53) FELDMAN BJ, STREEPER RS, FARESE RV, YAMAMOTO KR.
Myostatin modulates adipogenesis to generate
adipocytes with favorable metabolic effects. Proc
Natl Acad Sci U S A 2006; 103: 15675-15680.
54) ALLEN DL, CLEARY AS, SPEAKER KJ, LINDSAY SF, UYENISHI
J, REED JM, MADDEN MC, MEHAN RS. Myostatin, ac-
tivin receptor IIb, and follistatin-like-3 gene ex-
pression are altered in adipose tissue and skele-
tal muscle of obese mice. Am J Physiol En-
docrinol Metab 2008; 294: E918-927.
55) HITTEL DS, BERGGREN JR, SHEARER J, BOYLE K,
HOUMARD JA. Increased secretion and expression
of myostatin in skeletal muscle from extremely
obese women. Diabetes 2009; 58: 30-38.
56) LEE SJ, MCPHERRON AC. Regulation of myostatin
activity and muscle growth. Proc Natl Acad Sci U
S A 2001; 98: 9306-9311.
57) ALLEN DL, HITTEL DS, MCPHERRON AC. Expression
and function of myostatin in obesity, diabetes, and
exercise adaptation. Med Sci Sports Exerc 2011;
43: 1828-1835.
58) FEBBRAIO MA, PEDERSEN BK. Muscle-Derived inter-
leukin-6: Mechanisms for activation and possible
biological roles. FASEB J 2002; 16: 1335-1347.
59) ELLINGSGAARD H, HAUSELMANN I, SCHULER B, HABIB
AM, BAGGIO LL, MEIER DT, EPPLER E, BOUZAKRI K,
WUEEST S, MULLER YD, HANSEN AM, REINECKE M, KON-
RAD D, GASSMANN M, REIMANN F, HALBAN PA, GROMA-
DA J, DRUCKER DJ, GRIBBLE FM, EHSES JA, DONATH
MY. Interleukin-6 enhances insulin secretion by in-
creasing glucagon-like peptide-1 secretion from L
cells and alpha cells. Nat Med 2011; 17: 1481-
1489.
60) BOUZAKRI K, PLOMGAARD P, BERNEY T, DONATH MY, PED-
ERSEN BK, HALBAN PA. Bimodal effect on pancreatic
β-cells of secretory products from normal or in-
sulin-resistant human skeletal muscle. Diabetes
2011; 60: 1111-1121.
61) CAREY AL, STEINBERG GR, MACAULAY SL, THOMAS WG,
HOLMES AG, RAMM G, PRELOVSEK O, HOHNEN-BEHRENS
C, WATT MJ, JAMES DE, KEMP BE, PEDERSEN BK, FEB-
BRAIO MA. Interleukin-6 increases insulin-stimulated
glucose disposal in humans and glucose uptake
3719
Exercise and the Diabetic Syndrome
3720
and fatty acid oxidation in vitro via amp-activated
protein kinase. Diabetes 2006; 55: 2688-2697.
62) KELLY M, KELLER C, AVILUCEA PR, KELLER P, LUO Z, XI-
ANG X, GIRALT M, HIDALGO J, SAHA AK, PEDERSEN BK,
RUDERMAN NB. AMPK activity is diminished in tis-
sues of IL-6 knockout mice: The effect of exercise.
Biochem Biophys Res Commun 2004; 320: 449-
454.
63) MATTHEWS VB, ASTRÖM MB, CHAN MH, BRUCE CR,
KRABBE KS, PRELOVSEK O, AKERSTRÖM T, YFANTI C, BRO-
HOLM C, MORTENSEN OH, PENKOWA M, HOJMAN P,
ZANKARI A, WATT MJ, BRUUNSGAARD H, PEDERSEN BK,
FEBBRAIO MA. Brain-Derived neurotrophic factor is
produced by skeletal muscle cells in response to
contraction and enhances fat oxidation via activa-
tion of amp-activated protein kinase. Diabetologia
2009; 52: 1409-1418.
64) FERRIS LT, WILLIAMS JS, SHEN CL. The effect of acute
exercise on serum brain-derived neurotrophic fac-
tor levels and cognitive function. Med Sci Sports
Exerc 2007; 39: 728-734.
65) CHALDER M, WILES NJ, CAMPBELL J, HOLLINGHURST SP,
HAASE AM, TAYLOR AH, FOX KR, COSTELLOE C, SEARLE
A, BAXTER H, WINDER R, WRIGHT C, TURNER KM, CAL-
NAN M, LAWLOR DA, PETERS TJ, SHARP DJ, MONT-
GOMERY AA, LEWIS G. Facilitated physical activity as
a treatment for depressed adults: Randomised
controlled trial. Br Med J 2012; 344: e2758.
66) STEENSBERG A, FISCHER CP, KELLER C, MØLLER K, PEDER-
SEN BK. IL-6 enhances plasma il-1ra, IL-10, and
cortisol in humans. Am J Physiol Endocrinol
Metab 2003; 285: E433-437.
67) KELLER C, HELLSTEN Y, STEENSBERG A, PEDERSEN BK.
Differential regulation of IL-6 and tnf-alpha via
calcineurin in human skeletal muscle cells. Cy-
tokine 2006; 36: 141-147.
68) KELLER C, STEENSBERG A, HANSEN AK, FISCHER CP,
PLOMGAARD P, PEDERSEN BK. Effect of exercise, train-
ing, and glycogen availability on IL-6 receptor ex-
pression in human skeletal muscle. J Appl Physiol
(1985) 2005; 99: 2075-2079.
69) SERRANO AL, BAEZA-RAJA B, PERDIGUERO E, JARDÍ M,
MUÑOZ-CÁNOVES P. Interleukin-6 is an essential
regulator of satellite cell-mediated skeletal muscle
hypertrophy. Cell Metab 2008; 7: 33-44.
70) AL-SHANTI N, SAINI A, FAULKNER SH, STEWART CE. Ben-
eficial synergistic interactions of tnf-alpha and IL-6
in C2 skeletal myoblasts--potential cross-talk with
IGF system. Growth Factors 2008; 26: 61-73.
71) HASHIZUME M, HAYAKAWA N, SUZUKI M, MIHARA M. IL-
6/sil-6r trans-signalling, but not tnf-alpha induced
angiogenesis in a HUVEC and synovial cell co-cul-
ture system. Rheumatol Int 2009; 29: 1449-1454.
72) CAMPBELL IL, HOBBS MV, DOCKTER J, OLDSTONE MB,
ALLISON J. Islet inflammation and hyperplasia in-
duced by the pancreatic islet-specific overexpres-
sion of interleukin-6 in transgenic mice. Am J
Pathol 1994; 145: 157-166.
73) DICOSMO BF, PICARELLA D, FLAVELL RA. Local produc-
tion of human IL-6 promotes insulitis but retards
the onset of insulin-dependent diabetes mellitus
in non-obese diabetic mice. Int Immunol 1994; 6:
1829-1837.
74) CHOI SE, CHOI KM, YOON IH, SHIN JY, KIM JS, PARK
WY, HAN DJ, KIM SC, AHN C, KIM JY, HWANG ES, CHA
CY, SZOT GL, YOON KH, PARK CG. IL-6 protects pan-
creatic islet beta cells from pro-inflammatory cy-
tokines-induced cell death and functional impair-
ment in vitro and in vivo. Transpl Immunol 2004;
13: 43-53.
75) HAMRICK MW. A role for myokines in muscle-bone
interactions. Exerc Sport Sci Rev 2011; 39: 43-47.
76) BOSTRÖM P, WU J, JEDRYCHOWSKI MP, KORDE A, YE L,
LO JC, RASBACH KA, BOSTRÖM EA, CHOI JH, LONG JZ,
KAJIMURA S, ZINGARETTI MC, VIND BF, TU H, CINTI S,
HØJLUND K, GYGI SP, SPIEGELMAN BM. A PGC1-α-
dependent myokine that drives brown-fat-like de-
velopment of white fat and thermogenesis. Nature
2012; 481: 463-468.
77) YANG H, CHANG J, CHEN W, ZHAO L, QU B, TANG C, QI
Y, ZHANG J. Treadmill exercise promotes interleukin
15 expression in skeletal muscle and interleukin 15
receptor alpha expression in adipose tissue of
high-fat diet rats. Endocrine 2013; 43: 579-585.
78) GOLDSTEIN MS. Humoral nature of the hypo-
glycemic factor of muscular work. Diabetes 1961;
10: 232-234.
79) DELMONTE V, PEIXOTO EM, POGGIOLI R, ENFIELD G,
LUZI L, RICORDI C, ALEJANDRO R. Ten years' evalua-
tion of diet, anthropometry, and physical exercise
adherence after islet allotransplantation. Trans-
plant Proc 2013; 45: 2025-2028.
80) DELMONTE V, CODELLA R, PIEMONTI L, LA TORRE A,
BENEDINI S, MAFFI P, RICORDI C, LUZI L. Effects of ex-
ercise in a islet-transplanted half-marathon run-
ner: Outcome on diabetes management, training
and metabolic profile. Sport Sciences for Health
2014; 10: 49-52.
81) OSBORN O, OLEFSKY JM. The cellular and signaling
networks linking the immune system and metabo-
lism in disease. Nat Med 2012; 18: 363-374.
82) KAWANISHI N, YANO H, YOKOGAWA Y, SUZUKI K. Exer-
cise training inhibits inflammation in adipose tis-
sue via both suppression of macrophage infiltra-
tion and acceleration of phenotypic switching from
M1 to M2 macrophages in high-fat-diet-induced
obese mice. Exerc Immunol Rev 2010; 16: 105-
118.
83) PETERSEN AM, PEDERSEN BK. The anti-inflammatory
effect of exercise. J Appl Physiol (1985) 2005; 98:
1154-1162.
84) MATHUR N, PEDERSEN BK. Exercise as a mean to
control low-grade systemic inflammation. Media-
tors Inflamm 2008; 2008: 109502.
85) ESPOSITO K, PONTILLO A, DI PALO C, GIUGLIANO G,
MASELLA M, MARFELLA R, GIUGLIANO D. Effect of
weight loss and lifestyle changes on vascular in-
flammatory markers in obese women: A random-
ized trial. JAMA 2003; 289: 1799-1804.
86) PEDERSEN BK, AKERSTRÖM TC, NIELSEN AR, FISCHER CP.
Role of myokines in exercise and metabolism. J
Appl Physiol (1985) 2007; 103: 1093-1098.
R. Codella, L. Luzi, L. Inverardi, C. Ricordi
87) FISCHER CP. Interleukin-6 in acute exercise and
training: What is the biological relevance? Exerc
Immunol Rev 2006; 12: 6-33.
88) ESPOSITO K1, NAPPO F, MARFELLA R, GIUGLIANO G,
GIUGLIANO F, CIOTOLA M, QUAGLIARO L, CERIELLO A,
GIUGLIANO D. Inflammatory cytokine concentra-
tions are acutely increased by hyperglycemia in
humans: Role of oxidative stress. Circulation
2002; 106: 2067-2072.
89) STEENSBERG A, VAN HALL G, OSADA T, SACCHETTI M,
SALTIN B, KLARLUND PEDERSEN B. Production of inter-
leukin-6 in contracting human skeletal muscles can
account for the exercise-induced increase in plas-
ma interleukin-6. J Physiol 2000; 529: 237-242.
90) STEENSBERG A, FEBBRAIO MA, OSADA T, SCHJERLING P,
VAN HALL G, SALTIN B, PEDERSEN BK. Interleukin-6
production in contracting human skeletal muscle
is influenced by pre-exercise muscle glycogen
content. J Physiol 2001; 537: 633-639.
91) OSTROWSKI K, HERMANN C, BANGASH A, SCHJERLING P,
NIELSEN JN, PEDERSEN BK. A trauma-like elevation of
plasma cytokines in humans in response to tread-
mill running. J Physiol 1998; 513: 889-894.
92) STARKIE R, OSTROWSKI SR, JAUFFRED S, FEBBRAIO M,
PEDERSEN BK. Exercise and IL-6 infusion inhibit en-
dotoxin-induced tnf-alpha production in humans.
FASEB J 2003; 17: 884-6.
93) OSTROWSKI K, SCHJERLING P, PEDERSEN BK. Physical
activity and plasma interleukin-6 in humans--
effect of intensity of exercise. Eur J Appl Physiol
2000; 83: 512-515.
94) MATTHYS P, MITERA T, HEREMANS H, VAN DAMME J, BIL-
LIAU A. Anti-Gamma interferon and anti-inter-
leukin-6 antibodies affect staphylococcal entero-
toxin b-induced weight loss, hypoglycemia, and
cytokine release in d-galactosamine-sensitized
and unsensitized mice. Infect Immun 1995; 63:
1158-1164.
95) FIERS W. Tumor necrosis factor. Characterization
at the molecular, cellular and in vivo level. FEBS
Lett 1991; 285: 199-212.
96) FREEMAN BD, BUCHMAN TG. Interleukin-1 receptor
antagonist as therapy for inflammatory disorders.
Expert Opin Biol Ther 2001; 1: 301-308.
97) DINARELLO CA, SIMON A, VAN DER MEER JWM. Treat-
ing inflammation by blocking interleukin-1 in a
broad spectrum of diseases. Nat Rev Drug Dis-
cov 2012; 11: 633-652.
98) MOORE KW, DE WAAL MALEFYT R, COFFMAN RL, O'-
GARRA A. Interleukin-10 and the interleukin-10 re-
ceptor. Annu Rev Immunol 2001; 19: 683-765.
99) MAYNARD CL, WEAVER CT. Diversity in the contribu-
tion of interleukin-10 to t-cell-mediated immune
regulation. Immunol Rev 2008; 226: 219-233.
100) HONG EG, KO HJ, CHO YR, KIM HJ, MA Z, YU TY,
FRIEDLINE RH, KURT-JONES E, FINBERG R, FISCHER MA,
GRANGER EL, NORBURY CC, HAUSCHKA SD, PHILBRICK
WM, LEE CG, ELIAS JA, KIM JK. Interleukin-10 pre-
vents diet-induced insulin resistance by attenuat-
ing macrophage and cytokine response in skele-
tal muscle. Diabetes 2009; 58: 2525-2535.
101) MATTUSCH F, DUFAUX B, HEINE O, MERTENS I, ROST R.
Reduction of the plasma concentration of c-reac-
tive protein following nine months of endurance
training. Int J Sports Med 2000; 21: 21-24.
102) FALLON KE, FALLON SK, BOSTON T. The acute phase
response and exercise: Court and field sports. Br
J Sports Med 2001; 35: 170-173.
103) PEDERSEN BK, HOFFMAN-GOETZ L. Exercise and the
immune system: Regulation, integration, and
adaptation. Physiol Rev 2000; 80: 1055-1081.
104) STEWART LK, FLYNN MG, CAMPBELL WW, CRAIG BA,
ROBINSON JP, MCFARLIN BK, ET AL. Influence of exer-
cise training and age on CD14+ cell-surface ex-
pression of toll-like receptor 2 and 4. Brain Behav
Immun 2005; 19: 389-397.
105) KAISHO T, AKIRA S. Toll-Like receptor function and
signaling. J Allergy Clin Immunol 2006; 117: 979-
987; quiz 988.
106) TAKEDA K, KAISHO T, AKIRA S. Toll-Like receptors. An-
nu Rev Immunol 2003; 21: 335-376.
107) ATALAY M, OKSALA NK, LAAKSONEN DE, KHANNA S,
NAKAO C, LAPPALAINEN J, ROY S, HÄNNINEN O, SEN
CK. Exercise training modulates heat shock pro-
tein response in diabetic rats. J Appl Physiol
(1985) 2004; 97: 605-611.
108) MORIMOTO RI, SANTORO MG. Stress-Inducible re-
sponses and heat shock proteins: New pharma-
cologic targets for cytoprotection. Nat Biotechnol
1998; 16: 833-838.
109) MOYNAGH PN. The nf-kappab pathway. J Cell Sci
2005; 118: 4589-4592.
110) DRÖGE W. Free radicals in the physiological con-
trol of cell function. Physiol Rev 2002; 82: 47-95.
111) WENDLING U, FARINE JC. ORAL ADMINISTRATION OF HSP-
CONTAINING E. Coli extract OM-89 has suppressive
effects in autoimmunity. Regulation of autoimmune
processes by modulating peripheral immunity to-
wards hsp's? Biotherapy 1998; 10: 223-227.
112) WANG J, SONG H, TANG X, YANG Y, VIEIRA VJ, NIU Y, MA
Y. Effect of exercise training intensity on murine t-
regulatory cells and vaccination response. Scand J
Med Sci Sports 2012; 22: 643-652.
113) GLEESON M, BISHOP NC, STENSEL DJ, LINDLEY MR,
MASTANA SS, NIMMO MA. The anti-inflammatory ef-
fects of exercise: Mechanisms and implications
for the prevention and treatment of disease. Nat
Rev Immunol 2011; 11: 607-615.
114) FERNANDEZ MA, PUTTUR FK, WANG YM, HOWDEN W,
ALEXANDER SI, JONES CA. T regulatory cells con-
tribute to the attenuated primary CD8+ and CD4+
T cell responses to herpes simplex virus type 2 in
neonatal mice. J Immunol 2008; 180: 1556-1564.
115) SAKAGUCHI S. Naturally arising foxp3-expressing
CD25+CD4+ regulatory T cells in immunological
tolerance to self and non-self. Nat Immunol 2005;
6: 345-352.
116) CODELLA R, LANZONI G, ZOSO A, CAUMO A, MONTE-
SANO A, TERRUZZI IM, RICORDI C, LUZI L, INVERARDI L.
Moderate intensity training impact on the inflam-
matory status and glycemic profiles in NOD
mice. J Diabetes Res 2015, 2015: 737586.
3721
Exercise and the Diabetic Syndrome
3722
117) BALDUCCI S, ZANUSO S, NICOLUCCI A, FERNANDO F,
CAVALLO S, CARDELLI P, FALLUCCA S, ALESSI E, LETIZIA C,
JIMENEZ A, FALLUCCA F, PUGLIESE G. Anti-Inflammato-
ry effect of exercise training in subjects with type
2 diabetes and the metabolic syndrome is de-
pendent on exercise modalities and independent
of weight loss. Nutr Metab Cardiovasc Dis 2010;
20: 608-617.
118) BALDUCCI S1, ZANUSO S, NICOLUCCI A, DE FEO P, CAV-
ALLO S, CARDELLI P, FALLUCCA S, ALESSI E, FALLUCCA F,
PUGLIESE G. Effect of an intensive exercise inter-
vention strategy on modifiable cardiovascular risk
factors in subjects with type 2 diabetes mellitus:
A randomized controlled trial: The italian dia-
betes and exercise study (IDES). Arch Intern
Med 2010; 170: 1794-1803.
119) BEAVERS KM, BRINKLEY TE, NICKLAS BJ. Effect of exer-
cise training on chronic inflammation. Clin Chim
Acta 2010; 411: 785-793.
120) FIUZA-LUCES C, GARATACHEA N, BERGER NA, LUCIA A.
Exercise is the real polypill. Physiology (Bethes-
da) 2013; 28: 330-358.
121) KADOGLOU NP, ILIADIS F, ANGELOPOULOU N, PERREA D,
AMPATZIDIS G, LIAPIS CD, ALEVIZOS M. The anti-in-
flammatory effects of exercise training in patients
with type 2 diabetes mellitus. Eur J Cardiovasc
Prev Rehabil 2007; 14: 837-843.
122) NICKLAS BJ, HSU FC, BRINKLEY TJ, CHURCH T, GOOD-
PASTER BH, KRITCHEVSKY SB, PAHOR M. Exercise train-
ing and plasma c-reactive protein and inter-
leukin-6 in elderly people. J Am Geriatr Soc
2008; 56: 2045-2052.
123) WALTHER C, MÖBIUS-WINKLER S, LINKE A, BRUEGEL M,
THIERY J, SCHULER G, HALBRECHT R. Regular exercise
training compared with percutaneous interven-
tion leads to a reduction of inflammatory markers
and cardiovascular events in patients with coro-
nary artery disease. Eur J Cardiovasc Prev Re-
habil 2008; 15: 107-112.
124) NOBLE EE, BILLINGTON CJ, KOTZ CM, WANG CF. The
lighter side of BDNF. Am J Physiol Regul Integr
Comp Physiol 2011; 300: R1053-1069.
125) GEFFKEN DF, CUSHMAN M, BURKE GL, POLAK JF, SAKKI-
NEN PA, TRACY RP. Association between physical
activity and markers of inflammation in a healthy
elderly population. Am J Epidemiol 2001; 153:
242-250.
126) FISCHER CP, PLOMGAARD P, HANSEN AK, PILEGAARD H,
SALTIN B, PEDERSEN BK. Endurance training reduces
the contraction-induced interleukin-6 mrna ex-
pression in human skeletal muscle. Am J Physiol
Endocrinol Metab 2004; 287: E1189-1194.
127) LANCASTER GI, KHAN Q, DRYSDALE P, WALLACE F, JEUK-
ENDRUP AE, DRAYSON MT, GLEESON M. The physio-
logical regulation of toll-like receptor expression
and function in humans. J Physiol 2005; 563:
945-955.
128) GLEESON M, BISHOP N, OLIVEIRA M, MCCAULEY T,
TAULER P, MUHAMAD AS. Respiratory infection risk
in athletes: Association with antigen-stimulated
IL-10 production and salivary iga secretion.
Scand J Med Sci Sports 2012; 22: 410-417.
129) HERBST A, KORDONOURI O, SCHWAB KO, SCHMIDT F,
HOLL RW, DPV Initiative of the German Working
Group for Pediatric Diabetology Germany. Impact
of physical activity on cardiovascular risk factors
in children with type 1 diabetes: A multicenter
study of 23,251 patients. Diabetes Care 2007;
30: 2098-2100.
130) HUBER J, FRÖHLICH-REITERER EE, SUDI K, SUPPAN E,
WEINHANDL G, JASSER-NITSCHE H, AIGNER R, BORKEN-
STEIN MH. The influence of physical activity on
ghrelin and IGF-1/IGFBP-3 levels in children and
adolescents with type 1 diabetes mellitus. Pediatr
Diabetes 2010; 11: 383-385.
131) PHILLIPS MD, FLYNN MG, MCFARLIN BK, STEWART LK,
TIMMERMAN KL. Resistance training at eight-repeti-
tion maximum reduces the inflammatory milieu in
elderly women. Med Sci Sports Exerc 2010; 42:
314-325.
132) CUFF DJ, MENEILLY GS, MARTIN A, IGNASZEWSKI A,
TILDESLEY HD, FROHLICH JJ. Effective exercise
modality to reduce insulin resistance in women
with type 2 diabetes. Diabetes Care 2003; 26:
2977-2982.
133) JANSSEN I, FORTIER A, HUDSON R, ROSS R. Effects of
an energy-restrictive diet with or without exercise
on abdominal fat, intermuscular fat, and metabol-
ic risk factors in obese women. Diabetes Care
2002; 25: 431-438.
134) RICE B, JANSSEN I, HUDSON R, ROSS R. Effects of aer-
obic or resistance exercise and/or diet on glu-
cose tolerance and plasma insulin levels in
obese men. Diabetes Care 1999; 22: 684-691.
135) RIECHMAN SE, BALASEKARAN G, ROTH SM, FERRELL RE.
Association of interleukin-15 protein and inter-
leukin-15 receptor genetic variation with resis-
tance exercise training responses. J Appl Physiol
(1985) 2004; 97: 2214-2219.
136) NIELSEN AR1, MOUNIER R, PLOMGAARD P, MORTENSEN
OH, PENKOWA M, SPEERSCHNEIDER T, PILEGAARD H, PED-
ERSEN BK. Expression of interleukin-15 in human
skeletal muscle effect of exercise and muscle fibre
type composition. J Physiol 2007; 584: 305-312.
R. Codella, L. Luzi, L. Inverardi, C. Ricordi
